Suzetrigine (a NaV1.8 inhibitor) versus placebo for acute postoperative pain: A systematic review and meta-analysis of randomized controlled trials - PubMed
4 days ago
- #postoperative pain
- #NaV1.8 inhibitor
- #meta-analysis
- Suzetrigine, a NaV1.8 inhibitor, was compared to placebo for acute postoperative pain in a meta-analysis of randomized controlled trials.
- The study included 1,584 participants (1,009 on suzetrigine, 575 on placebo) with a mean age of 44.9 years, predominantly women (92.3%).
- Suzetrigine significantly reduced pain at 24 hours (mean difference = -0.93) and 48 hours (mean difference = -1.02) compared to placebo.
- Subgroup analyses showed consistent benefits across different surgery types (abdominoplasty and bunionectomy).
- Adverse events like nausea and dizziness were less frequent in the suzetrigine group, with no significant differences in headache, vomiting, or constipation.
- Risk of bias was low in two studies and raised some concerns in two others.
- The study concluded that suzetrigine modestly reduces postoperative pain but could not assess opioid-sparing effects due to inconsistent reporting of opioid consumption.